Nouvelles.droit.org

🕒
RSS JSON
future entrepreneurship ftc events market jenavalve companies technological potentially aortic edwards conference condition mega redefining medical advancements tavr innovation treat two devices acquisition heart proposed with tie2024 deal international today would broadcasting var
2 Résultats (1 - 2)
Future Unleashed: The Mega-Conference That’s Redefining Technology and Entrepreneurship (Business Today)
: Key Takeaways: Introduction to Innovation A Legacy of Success Following a highly acclaimed event last year, EAI is gearing up to host the 5th iteration of its International Conference on Technology, Innovation, Entrepreneurship, and Education (TIE2024). The conference promises to be an epicenter of technological advancements, showcasing innovations that intersect with significant global sporting events. Technology in the Spotlight Broadcasting Breakthroughs TIE2024 will delve into the technological advancements shaping the broadcasting, networking, and dissemination of content for major international sports events. The conference aims to bridge the gap between technological innovation and practical application, offering insights into the future of The post Future Unleashed: The Mega-Conference That’s Redefining Technology and Entrepreneurship appeared first on Business Today
FTC Challenges Anticompetitive Medical Device Deal (Federal Trade Commission Concurrence communiqués)
: The Federal Trade Commission today moved to block medical device supplier Edwards Lifesciences Corp.’s (Edwards) proposed acquisition of JenaValve Technology, Inc. (JenaValve) due to concerns that the acquisition would limit patient access to lifesaving medical devices used to treat a potentially fatal heart condition. The FTC alleges that over the span of two days in July 2024, Edwards executed agreements to acquire both JenaValve and JC Medical, the two leading companies competing to bring to market transcatheter aortic valve replacement devices that treat a heart condition called aortic regurgitation (TAVR-AR devices). Edwards closed its acquisition of JC Medical in August 2024, and its proposed $945 million acquisition of JenaValve would combine the only two companies with ongoing clinical trials in the United States for a TAVR-AR device. The deal threatens to reduce competition in the TAVR-AR market, likely resulting in reduced innovation, diminished product quality, and potentially increased prices for[...]